BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is a stock Jim Cramer advised against due to its poor performance history. The company focuses on rare disease treatments, recently finalizing the $700 million acquisition of Astria Therapeutics, adding navenibart, a Phase 3 therapy for hereditary angioedema, to its portfolio.

While BCRX shows potential, other AI stocks may offer better returns with less risk. Investors seeking an undervalued AI stock can explore opportunities in the market. For more insights, check out the free report on the best short-term AI stock for potential growth and benefits from current economic trends.

Read more at Yahoo Finance: “Just Stay Away From That”